Profile data is unavailable for this security.
About the company
CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. The Company’s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The Company is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
- Revenue in USD (TTM)0.00
- Net income in USD-2.54m
- Incorporated2021
- Employees8.00
- LocationCERo Therapeutics Holdings Inc201 Haskins Way, Suite 230SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (215) 731-9450
- Fax+1 (302) 636-5454
- Websitehttps://www.phoenixbiotechacquisitioncorp.com/
Mergers & acquisitions
Acquired company | CERO:NMQ since announced | Transaction value |
---|---|---|
CERo Therapeutics Inc | -91.47% | 50.00m |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Actavia Life Sciences Inc | 0.00 | -4.44m | 13.04m | 1.00 | -- | -- | -- | -- | -0.0074 | -0.0074 | 0.00 | -0.0027 | 0.00 | -- | -- | 0.00 | -10,235.89 | -158.17 | -- | -- | -- | -- | -- | -- | -- | -21.20 | -- | -- | -- | -- | -547.04 | -- | -- | -- |
Inhibikase Therapeutics Inc | 195.98k | -19.20m | 13.06m | 8.00 | -- | 1.73 | -- | 66.65 | -3.38 | -3.38 | 0.034 | 1.05 | 0.01 | -- | 6.08 | 24,497.50 | -97.88 | -66.49 | -118.76 | -85.55 | -- | -- | -9,797.30 | -1,139.14 | -- | -- | 0.00 | -- | 111.03 | -42.21 | -5.40 | -- | -- | -- |
Medical Marijuana Inc | -100.00bn | -100.00bn | 13.07m | -- | -- | 0.121 | -- | -- | -- | -- | -- | 0.019 | -- | -- | -- | -- | -- | -22.66 | -- | -23.11 | -- | 70.58 | -- | -145.52 | 1.79 | -- | 0.0479 | -- | 26.30 | 39.07 | 141.59 | -- | -0.016 | -- |
Mira Pharmaceuticals Inc | 0.00 | -12.36m | 13.08m | 3.00 | -- | 4.14 | -- | -- | -0.8276 | -0.8276 | 0.00 | 0.2136 | 0.00 | -- | -- | 0.00 | -587.64 | -- | -1,721.90 | -- | -- | -- | -- | -- | -- | -2.63 | 0.00 | -- | -- | -- | -69.77 | -- | -- | -- |
Check Cap Ltd | 0.00 | -17.57m | 13.28m | 85.00 | -- | 0.5607 | -- | -- | -3.00 | -3.00 | 0.00 | 4.05 | 0.00 | -- | -- | -- | -49.87 | -54.23 | -53.46 | -60.24 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 8.06 | -- | -2.46 | -- |
Avalo Therapeutics Inc | 1.45m | -142.88m | 13.55m | 19.00 | -- | -- | -- | 9.34 | -318.69 | -318.69 | 3.02 | -97.75 | 0.0181 | -- | 3.25 | 76,315.79 | -178.64 | -99.64 | -- | -154.42 | 54.90 | 84.69 | -9,853.73 | -613.58 | -- | -0.2415 | -- | -- | -89.34 | -22.83 | 24.28 | -- | -22.48 | -- |
CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 13.82m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
Pieris Pharmaceuticals Inc | 40.93m | -16.25m | 13.84m | 46.00 | -- | 0.5901 | -- | 0.3381 | -12.74 | -12.74 | 34.05 | 17.76 | 0.7324 | -- | 28.25 | 889,717.40 | -29.09 | -28.41 | -52.98 | -39.69 | -- | -- | -39.71 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
Edesa Biotech Inc | 0.00 | -7.25m | 14.09m | 16.00 | -- | 3.26 | -- | -- | -2.37 | -2.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -84.50 | -- | -107.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
Imunon Inc | 0.00 | -18.85m | 14.20m | 33.00 | -- | 1.67 | -- | -- | -2.02 | -2.02 | 0.00 | 0.9041 | 0.00 | -- | -- | 0.00 | -66.82 | -50.18 | -91.53 | -60.27 | -- | -- | -- | -5,725.88 | -- | -- | 0.00 | -- | -100.00 | -- | 45.64 | -- | 26.69 | -- |
Vicapsys Life Sciences Inc | 0.00 | -1.08m | 14.24m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
Sunshine Biopharma Inc | 26.74m | -4.09m | 14.30m | 44.00 | -- | 0.0303 | -- | 0.5349 | -13.35 | -13.35 | 76.96 | 24.96 | 0.9081 | 3.13 | 11.58 | 607,722.50 | -13.88 | -101.52 | -17.99 | -137.04 | 33.15 | 35.47 | -15.29 | -165.33 | 3.23 | -- | 0.00 | -- | 454.42 | -- | 83.15 | -- | 110.99 | -- |
Kiora Pharmaceuticals Inc | 16.00m | 2.28m | 14.33m | 12.00 | -- | 0.4106 | 6.17 | 0.8958 | -1.60 | -1.60 | 1.21 | 1.33 | 0.5427 | -- | 8.64 | 1,333,333.00 | 9.52 | -70.52 | 10.17 | -81.86 | -- | -- | 17.55 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
Mannatech Inc | 127.23m | -1.66m | 14.44m | 213.00 | -- | 1.38 | -- | 0.1135 | -0.899 | -0.899 | 68.07 | 5.54 | 2.77 | 1.93 | 561.74 | 597,342.80 | -3.62 | 4.39 | -9.67 | 9.16 | 78.01 | 77.87 | -1.31 | 1.72 | 0.5584 | -- | 0.1384 | 88.33 | -3.83 | -5.33 | 50.13 | -- | -20.38 | -- |
Holder | Shares | % Held |
---|---|---|
Jane Street Capital LLCas of 31 Mar 2024 | 26.52k | 0.18% |
Birchview Capital LPas of 31 Mar 2024 | 12.97k | 0.09% |
Geode Capital Management LLCas of 31 Mar 2024 | 10.59k | 0.07% |
FNY Capital Management LPas of 31 Mar 2024 | 10.50k | 0.07% |
Kestra Private Wealth Services LLCas of 31 Mar 2024 | 10.00k | 0.07% |
Pineridge Advisors LLCas of 31 Mar 2024 | 300.00 | 0.00% |
JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 2.00 | 0.00% |
Clear Street LLCas of 31 Mar 2024 | 0.00 | 0.00% |
Meteora Capital LLCas of 31 Mar 2024 | 0.00 | 0.00% |
Goldman Sachs & Co. LLCas of 30 Dec 2022 | 0.00 | 0.00% |